聚酰胺层析法分离纯化银杏叶总黄酮的研究

目的:对聚酰胺层析法分离纯化银杏叶总黄酮进行研究。方法通过静态吸附确定聚酰胺的最大吸附量为,动态吸附后考察不同浓度乙醇的洗脱曲线及纯度,定量采用HPLC定量测定。结果每克聚酰胺粉(已处理过)平均吸附量为:115mg;70%乙醇洗脱较合适,纯度可达到15.60%。     

聚酰胺对独脚金总黄酮的纯化工艺研究

目的 研究聚酰胺分离纯化独脚金总黄酮的工艺条件.方法 以紫外可见分光光度法测定独脚金样品溶液中总黄酮的含量为指标,考察多个工艺参数.结果 聚酰胺对独脚金的总黄酮有良好的吸附作用,其吸附分离工艺条件的药液浓度为1.12～2.24 mg/mL,以2BV/h吸附速率进行吸附,95%乙醇250 mL洗脱效果最佳.结论 该方法简单易行,分离效果良好,适于独脚金中总黄酮的分离纯化.     

黄芩中汉黄芩素的提取制备

为建立制备大量高纯度汉黄芩素的方法,将中药黄芩50g用pH 5水水解12h,再用95％的乙醇提取,得到的提取物浸膏,过30～60目的聚酰胺树脂柱纯化,将含有汉黄芩素的洗脱物采用高速逆流色谱（HSCCC）进行分离.通过该方法制得汉黄芩素525mg,纯度为98.7％.     

A new modification of the individually designed polymer implant visible in X-ray for orbital reconstruction

Orbital reconstruction makes higher demands on symmetry and axial precision than other parts of the skull, because the position of the eye globe determines proper vision. The aim of this study is to evaluate titanium surface marking of polymers (UHMW-PE and PA6) to check implants position in CT examination and clinical application of such modified individual implant.One hundred and twenty-four polymer blocks were prepared. New method of ultrasounds welding to connect the titanium markers to the polymer surface was developed and tested. Titanium marked polymer blocks were examined by CT to evaluate the quality of the cover. Then, two modified UHMW-PE individual implants were applied clinically and implant position was checked by CT.The biggest titanium cover was in PA6 [25 ± 18% of processed surface] and for UHMW-PE [19 ± 12%] without significance [p = 0.14]. Both covers were visible in CT. Clinical application revealed proper reconstruction, uneventful post-operational outcome and well visible surface of the implants in CT.The conducted tests make it possible to determine the suitability of ultrasonic technology for the deposition of titanium markers in polymer. The clinical use of modified individual implants allows to confirm the correct position of the implants because they are accurate visible in CT.     

Induction of endometrial mesenchymal stem cells into tissue-forming cells suitable for fascial repair

Pelvic organ prolapse is a major hidden burden affecting almost one in four women. It is treated by reconstructive surgery, often augmented with synthetic mesh. To overcome the growing concerns of using current synthetic meshes coupled with the high risk of reoperation, a tissue engineering strategy has been developed, adopting a novel source of mesenchymal stem cells. These cells are derived from the highly regenerative endometrial lining of the uterus (eMSCs) and will be delivered in vivo using a new gelatin-coated polyamide scaffold. In this study, gelatin properties were optimized by altering the gelatin concentration and extent of crosslinking to produce the desired gelation and degradation rate in culture. Following cell seeding of uncoated polyamide (PA) and gelatin-coated meshes (PA + G), the growth rate of eMSCs on the PA + G scaffolds was more than that on the PA alone, without compromising cell shape. eMSCs cultured on the PA + G scaffold retained their phenotype, as demonstrated by W5C5/SUSD2 (eMSC-specific marker) immunocytochemistry. Additionally, eMSCs were induced to differentiate into smooth muscle cells (SMC), as shown by immunofluorescence for smooth muscle protein 22 and smooth muscle myosin heavy chain. eMSCs also differentiated into fibroblast-like cells when treated with connective tissue growth factor with enhanced detection of Tenascin-C and collagen type I as well as new tissue formation, as seen by Masson’s trichrome. In summary, it was demonstrated that the PA + G scaffold is an appropriate platform for eMSC delivery, proliferation and differentiation into SMC and fibroblasts, with good biocompatibility and the capacity to regenerate neo-tissue.     

n-HA/PA66复合生物活性人工椎体支撑植骨治疗胸腰椎爆裂型骨折合并截瘫

目的:探讨用前路椎管减压、自行研制的纳米羟基磷灰石/聚酰胺66(n-HA/PA66)复合生物活性人工椎体支撑植骨治疗胸腰椎爆裂型骨折合并截瘫的临床疗效。方法:2003年12月—2006年1月收治胸腰椎爆裂型骨折合并截瘫40例,年龄17～62岁。受伤部位:T_(12)5例、L_1 16例、L_2 13例、L_3 6例。神经损害按Frankel分级:A级7例、B级19例、C级8例、D级6例。所有病例均行前路椎管减压、n-HA/PA66复合生物活性人工椎体支撑植骨、钛钉板或钉棒系统内固定。结果:所有病例术后均获得6～25个月(平均13个月)的随访。神经功能:除5例Franel A级和2例D级无变化外,其余均有1～2级的改善。其中由A级到B级2例;B级到C级7例,B级到D级12例;C级到D级5例,C级到E级3例;D级到E级4例。36例伤椎接近解剖复位,6例复位良好。术前伤椎前缘高度平均为椎体的42.8%,术后平均为90.5%,重建的椎体高度无丢失。矢状面Cobb角术前平均为28.4°,术后平均为14.6°。n-HA/PA66复合生物活性人工椎体于术后3～6个月骨性融合。无感染、无椎体移位和断钉等并发症。结论:前路n-HA/PA66复合生物活性人工椎体支撑植骨能有效恢复和维持伤椎的结构和高度,可避免取自体髂骨植骨,是一种有效的脊柱前路重建方法。     

Characterization and antibacterial properties of N-halamine-derivatized cross-linked polymethacrylamide nanoparticles

N-halamine-derivatized cross-linked polymethacrylamide nanoparticles with sizes ranging between 18 ± 2.0 and 460 ± 60 nm were prepared via surfactant-free dispersion co-polymerization of methacrylamide (MAA) and the cross-linking monomer N,N-methylenebisacrylamide (MBAA) in an aqueous continuous phase, followed by a chlorination process using sodium hypochlorite. The effect of various polymerization parameters (monomer concentration, initiator type and concentration, polymerization duration, polymerization temperature, and the weight ratio [MBAA]/[MAA]) on the size and size distribution of the produced cross-linked P(MAA–MBAA) nanoparticles was elucidated. The effect of various chlorination parameters (hypochlorite concentration, chlorination period and temperature) on the bound oxidative chlorine atom (Cl) content of the P(MAA–MBAA) nanoparticles was also investigated. The bactericidal activity of these chloramine-derivatized nanoparticles was tested against two common bacterial pathogens (Escherichia coli and Staphylococcus aureus), and they were found to be highly potent. Furthermore, these nanoparticles also exerted their antimicrobial activity against multi-drug resistant (MDR) bacteria, further demonstrating their efficacy.     

n-HA/PA66复合生物活性融合器在颈椎病前路减压融合术中的初步应用研究

分析52例颈椎病行前路减压、n-HA/PA66复合生物活性融合器植骨、钛钉板系统内固定颈椎前路重建手术患者的临床资料,探讨自行研制的纳米羟基磷灰石/聚酰胺66(n-HA/PA66)复合生物活性融合器在颈椎病前路减压固定融合手术中的初步临床疗效。所有术后均获得6～25个月(平均13个月)的随访。患者术前症状均得到改善,JOA评分术前平均为10.4分,术后为15.7分。n-HA/PA66复合生物活性融合器于术后3～6个月骨性融合。颈椎生理曲度、椎间高度、颈椎稳定性均维持良好。无融合器下沉、塌陷、移位发生,无感染、内固定物松动、脱落、断裂等并发症。n-HA/PA66复合生物活性融合器能有效重建和维持颈椎体的结构和高度,可能是一种理想的颈椎植骨替代材料。     

纳米羟基磷灰石/聚酰胺66复合骨填充材料修复良性骨肿瘤骨缺损临床疗效观察

目的观察颗粒型纳米羟基磷灰石/聚酰胺66(nano-hydroxyapatite/polyamide66,n-HA/PA66)复合骨修复材料修复良性骨肿瘤骨缺损的疗效和生物安全性。方法2003年1月～2005年5月,选取37例良性骨肿瘤患者,男21例,女16例,其中1例为2处病变;年龄19～58岁,平均38.5岁。骨纤维结构不良11例(12侧),骨囊肿14例,骨巨细胞瘤级10例,内生软骨瘤2例。肿瘤大小为1.0cm×0.7cm×0.4cm～10.0cm×4.0cm×3.0cm;肿瘤位于股骨近端12例(13侧),远端7例,胫骨近端9例,肱骨近端5例,指骨2例,掌骨和跟骨各1例。行肿瘤刮除术,瘤腔用颗粒型n-HA/PA66填充,伤口常规缝合;术后观察伤口愈合情况,局部炎性反应,排斥反应,全身毒性,瘤腔愈合和患肢功能的恢复情况。结果术后1例伤口感染,余伤口期愈合。局部炎性反应轻微,无排斥反应和全身毒性反应。术后全部获随访5～33个月,术后3～5.5个月可见新骨长入n-HA/PA66填充区,下肢在术后8个月可完全负重,上肢在术后5个月可完成日常活动。结论颗粒型n-HA/PA66复合骨修复材料具有良好生物安全性、相容性和骨传导性,可用于良性骨肿瘤骨缺损的修复。     

聚酰胺-氨纳米微粒介导5-氟尿嘧啶联合小RNA-21抑制乳腺癌细胞生长的研究

Objective To study the effect of PAMAM-mediated 5-fluorouracil combined with miR-21 inhibitor gene therapy to suppress MCF-7 human breast cancer cell growth in vitro. Methods 5-Fu/PAMAM complex was prepared by dialysis method and then incubated with miR-21 inhibitor at room temperature. Transmission electronic microscopy (TEM) was performed to observe the morphology of the nanoparticles. The drug loading efficiency and encapsulation efficiency was determined by ultraviolet spectroscopy (UV). The transfection of PAMAM dendrimer was detected by flow cytometry. MTT assay was carried out to determine MCF-7 cell growth survival rate. Cell apoptosis was analyzed by flow-cytometry. Transwell assay was performed to detect invasion ability after MCF-7 cells treated with 5-Fu chemotherapy combined with miR-21 inhibitor gene therapy. Results The morphology of the complex was sphere observed under TEM. Encapsulation efficiency and loading efficiency of drug were (66. 21±4. 11)% and (31.77±0. 73)% , respectively. Flow cytometry revealed that 5-Fu/PAMAM transfection efficiency was (60.54 ±6. 97)%. 5-Fu combined with miR-21 inhibitor treatment significantly suppressed cell growth, and the survival rate was only (55. 85±3. 71)% on the 6th day of the observation period. The apoptosis rate in combined treatment group was (18. 32±2.42)% , dramatically higher than in control group (F=58. 326,P<0. 01). In combined treatment group, the number of invasion cells was only 18. 96 ±3. 14, suggesting the greatly decreased invasion ability of MCF-7 cells (F=16. 409,P < 0. 01). Conclusion PAMAM could effectively deliver miR-21 inhibitor and 5-Fu simultaneously, and combined therapy can suppress growth of MCF-7 cells effectively in vitro.